NDA 019018 · B Braun
Trophamine 10%
Amino Acids · Injection · Amino Acid
Last checked: Nov 20, 2026Latest source record: Oct 26, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Jul 20, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30,323
6,603 Phase 3, 2,682 recruiting
FAERS reports
28
26 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 19, 2026.
INDICATIONS AND USAGE TrophAmine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring TPN via either central or peripheral infusion routes. Parenteral nutrition with TrophAmine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. See WARNINGS , PRECAUTIONS , Pediatric Use , AND DOSAGE AND ADMINISTRATION . Central Venous Nutrition Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants, or those requiring long-term parenteral nutrition. Peripheral Parenteral Nutrition For moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5-10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 20, 1984 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- TROPHAMINE 10% · AMINO ACIDS 10% (10GM/100ML) · INJECTABLE, INJECTION · Prescription
- TROPHAMINE · AMINO ACIDS 6% (6GM/100ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Amino Acids" as an intervention, any sponsor and status, largest first.
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsPivotal-lookingNot yet recruiting
Tor Biering-SørensenAcademic, hospital or other
NCT07790523 · 410,000 participants (planned) · Start Sep 1, 2026 · Primary completion May 31, 2028
Drug: mCombriax® (mRNA-1083); Efluelda® (TIV-HD) and Spikevax® (mRNA-1273) · For: COVID-19; Influenza
Sites: Hellerup, Denmark; Søborg, Denmark; Santiago de Compostela, Spain
- Community Level Interventions for Pre-eclampsiaPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT01911494 · 87,500 participants (planned) · Start Sep 2013 · Primary completion May 2018
Drug: Magnesium Sulfate; Methyldopa · For: Pre-eclampsia; Hypertension, Pregnancy Induced
Sites: Belagavi, India; Maputo, Mozambique; Sagamu, Nigeria · 4 sites in all
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated DonorsPivotal-lookingRecruiting
Center for International Blood and Marrow Transplant ResearchResearch network
NCT00785525 · 60,000 participants (planned) · Start Feb 1997 · Primary completion Jan 2030
Drug: Filgrastim · For: Healthy
Sites: Boca Raton, Florida; Rockville, Maryland; Minneapolis, Minnesota · 4 sites in all
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy IndividualsPivotal-lookingCompleted
BioNTech SEIndustry
NCT04368728 · 46,969 participants · Start Apr 29, 2020 · Primary completion Feb 10, 2023
Drug: BNT162b1; BNT162b2 and 1 more · For: SARS-CoV-2 Infection; COVID-19
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 175 sites in all
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19Pivotal-lookingCompleted
Tor Biering-SørensenAcademic, hospital or other
NCT07279766 · 41,060 participants · Start Dec 11, 2025 · Primary completion Aug 26, 2026
Drug: mRNA-1273 (Moderna COVID-19 vaccine) · For: COVID-19
Sites: Hellerup, Denmark; Søborg, Denmark
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
- A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19Pivotal-lookingCompleted
ModernaTX, Inc.Moderna (MRNA)
NCT04470427 · 30,415 participants · Start Jul 27, 2020 · Primary completion Dec 29, 2022
Drug: mRNA-1273; Placebo · For: SARS-CoV-2
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cholestasis9
- liver function test abnormal9
- condition aggravated8
- bacterial infection4
- blood bilirubin increased4
- catheter sepsis4
- bilirubin conjugated increased3
- disseminated intravascular coagulation3
- pyrexia3
- anaemia2
- catheter related infection2
- glycosuria2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2018 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 10, 2026
TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The Effect of Amino Acids on Wound Healing: A Systematic Review and Meta-Analysis on Arginine and Glutamine.
Arribas-López E, Zand N, Ojo O, et al. · Nutrients 2021 · Meta-Analysis, Systematic Review
- Efficacy of dietary supplements on improving sleep quality: a systematic review and meta-analysis.
Chan V, Lo K · Postgrad Med J 2022 · Meta-Analysis, Systematic Review
- β-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis.
Saunders B, Elliott-Sale K, Artioli GG, et al. · Br J Sports Med 2017 · Meta-Analysis, Systematic Review
- Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses.
Gielen E, Beckwée D, Delaere A, et al. · Nutr Rev 2021 · Meta-Analysis, Systematic Review
- Protein interventions augment the effect of resistance exercise on appendicular lean mass and handgrip strength in older adults: a systematic review and meta-analysis of randomized controlled trials.
Kirwan RP, Mazidi M, Rodríguez García C, et al. · Am J Clin Nutr 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Biomarkers shared by frailty and sarcopenia in older adults: A systematic review and meta-analysis.
Picca A, Coelho-Junior HJ, Calvani R, et al. · Ageing Res Rev 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: B Braun · Also marketed as Trophamine
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.